Table 4.
Safety profile and common AEs of all patients and those who received different ixazomib-based regimen
| All patients (N = 85) | IRd regimen (n = 38) | Other triplet regimena (n = 22) | Id doublet regimen (n = 25) | |
|---|---|---|---|---|
| Overall safety profile, n (%) | ||||
| Any grade ≥ 3 AE | 25 (29.4) | 9 (23.7) | 7 (31.8) | 9 (36.0) |
| AE leading to discontinuation of ixazomib | 12 (14.1) | 5 (13.2) | 3 (13.6) | 4 (16.0) |
| AE leading to dose reduction of ixazomib | 3 (3.5) | 1 (2.6) | 2 (9.1) | 0 |
| Common hematologic AEs, n (%) | ||||
| Neutropenia | 24 (28.2) | 11 (28.9) | 8 (36.4) | 5 (20.0) |
| Thrombocytopenia | 24 (28.2) | 7 (18.4) | 8 (36.4) | 9 (36.0) |
| Anemia | 27 (31.8) | 12 (31.6) | 8 (36.4) | 10 (40.0) |
| Lymphocytopenia | 29 (34.1) | 14 (36.8) | 5 (22.7) | 12 (31.6) |
| Common non-hematologic AEs, n (%) | ||||
| Diarrhea | 16 (18.8) | 4 (10.5) | 3 (13.6) | 9 (36.0) |
| Nausea | 8 (9.4) | 0 | 5 (22.7) | 3 (12.0) |
| Vomiting | 8 (9.4) | 0 | 5 (22.7) | 3 (12.0) |
| Constipation | 15 (17.6) | 8 (21.1) | 2 (9.1) | 5 (20.0) |
| Fatigue | 25 (29.4) | 11 (28.9) | 5 (22.7) | 9 (36.0) |
| Upper respiratory tract infection | 3 (3.5) | 1 (2.6) | 0 | 2 (8.0) |
| Rashes or other skin and subcutaneous tissue disorder except herpes zoster | 20 (23.5) | 16 (42.1) | 1 (4.5) | 3 (12.0) |
| Herpes zoster | 2 (2.4) | 0 | 0 | 2 (8.0) |
| Peripheral edema | 11 (12.9) | 4 (10.5) | 1 (4.5) | 6 (24.0) |
| Pneumonia | 10 (11.8) | 5 (13.2) | 2 (9.1) | 3 (12.0) |
| Peripheral neuropathy | 5 (5.9) | 1 (2.6) | 0 | 4 (16.0) |
AE, adverse event
aThis subgroup included Id plus other chemotherapeutics or monoclonal antibody: 11 cases with doxorubicin, 7 with cyclophosphamide, 3 with thalidomide and 1 with daratumumab